BRAF and cancer: Their efficacy has been curtailed by the toxicity of the side effects and development of resistance in patients as well as the emergence of secondary cancers such as cutaneous squamous cell carcinoma due to the activation of BRAF inhibitor-induced paradoxical activation of MAPK pathway.